Join
Live feed
·
PRReleasevia Quantisnow
Oncorus Inc. logo

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ONCR· Oncorus Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONCR (Oncorus Inc.) and more on Quantisnow.